Literature DB >> 18633356

Structural comparisons of class I phosphoinositide 3-kinases.

L Mario Amzel1, Chuan-Hsiang Huang, Diana Mandelker, Christoph Lengauer, Sandra B Gabelli, Bert Vogelstein.   

Abstract

Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth. One of these kinases, PI3Kalpha, is frequently mutated in diverse tumour types. The recently determined structure of PI3Kalpha reveals features that distinguish this enzyme from related lipid kinases. In addition, wild-type PI3Kgamma differs from PI3Kalpha by a substitution identical to a PI3Kalpha oncogenic mutant (His1047Arg) that might explain the differences in the enzymatic activities of the normal and mutant PI3Kalpha. Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633356      PMCID: PMC2847604          DOI: 10.1038/nrc2443

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  48 in total

Review 1.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

Review 2.  Phosphoinositide 3-kinase: from viral oncoprotein to drug target.

Authors:  Peter K Vogt; Andreas G Bader; Sohye Kang
Journal:  Virology       Date:  2006-01-05       Impact factor: 3.616

3.  Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

Authors:  Douglas A Levine; Faina Bogomolniy; Cindy J Yee; Alex Lash; Richard R Barakat; Patrick I Borgen; Jeff Boyd
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

Authors:  Lao H Saal; Karolina Holm; Matthew Maurer; Lorenzo Memeo; Tao Su; Xiaomei Wang; Jennifer S Yu; Per-Olof Malmström; Mahesh Mansukhani; Jens Enoksson; Hanina Hibshoosh; Ake Borg; Ramon Parsons
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

5.  Functional analysis of PIK3CA gene mutations in human colorectal cancer.

Authors:  Tsuneo Ikenoue; Fumihiko Kanai; Yohko Hikiba; Toshiyuki Obata; Yasuo Tanaka; Jun Imamura; Miki Ohta; Amarsanaa Jazag; Bayasi Guleng; Keisuke Tateishi; Yoshinari Asaoka; Masayuki Matsumura; Takao Kawabe; Masao Omata
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

6.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

7.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

8.  Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

Authors:  Jeffrey D Carson; Glenn Van Aller; Ruth Lehr; Robert H Sinnamon; Robert B Kirkpatrick; Kurt R Auger; Dashyant Dhanak; Robert A Copeland; Richard R Gontarek; Peter J Tummino; Lusong Luo
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

9.  p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma.

Authors:  Sabine Suire; John Coadwell; G John Ferguson; Keith Davidson; Phillip Hawkins; Len Stephens
Journal:  Curr Biol       Date:  2005-03-29       Impact factor: 10.834

10.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

View more
  40 in total

1.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

2.  Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes.

Authors:  Hiroyuki Takai; Yihu Xie; Titia de Lange; Nikola P Pavletich
Journal:  Genes Dev       Date:  2010-08-27       Impact factor: 11.361

Review 3.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 4.  Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Aspects Med       Date:  2010-02-20

Review 5.  Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Authors:  Sandra B Gabelli; Krisna C Duong-Ly; Evan T Brower; L Mario Amzel
Journal:  Adv Enzyme Regul       Date:  2010-10-28

6.  A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.

Authors:  Hashem A Dbouk; Huan Pang; Andras Fiser; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

Review 7.  Crossroads of PI3K and Rac pathways.

Authors:  Carlo C Campa; Elisa Ciraolo; Alessandra Ghigo; Giulia Germena; Emilio Hirsch
Journal:  Small GTPases       Date:  2015-05-05

Review 8.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

9.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 10.  Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Authors:  Sandra B Gabelli; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Biochim Biophys Acta       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.